Want to join the conversation?
$AMGN 2Q15 Call: On an adjusted basis, cost of sales margin at 15.1% improved 0.8 points driven by lower royalties and a higher average net sales price. R&D expenses at $918MM were down 6% vs. 2Q14. SG&A expenses were up 2% on a YoverY basis. Total OpEx declined 1% YonY and increased 9% sequentially.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?